中國抗體-B(03681.HK)上市翌日股價續挫12% 華領(02552.HK)再挫19%
仍未有任何盈利中國抗體-B(03681.HK)繼首掛日股價低收挫21%後,今早進一步跌至5.22元才喘定,半日收5.27元,續挫12%,成交1,603萬股,涉資8,669萬元。中國抗體是專門研發、製造及商業化免疫性疾病療法的香港生物製藥公司。是次以每股7.6元上市淨籌12.86億元,主要用作研發和商業化其核心產品及建設蘇州生產基地等。
另一隻仍未錄得盈利去年9月才以每股8.28元上市的華領醫藥(02552.HK)繼昨天指無法保證治療糖尿病新藥dorzagliatin(HMS5552)明年次季可成功開發導致股價倒跌16%後,今天進一步下挫,最多再挫28%低見4.1元再創上市新低,半日收4.64元,續挫19%,成交284萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.